Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer (NCT05081024)
🩺 Plain-English Summary (8th-Grade Level)
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.
Who can join: Review the eligibility criteria below.
Location: OHSU Knight Cancer Institute — Portland, Oregon
Age range: 18 Years
🧪 Interventions in This Study
- Biopsy (PROCEDURE)
- Biospecimen Collection (PROCEDURE)
- Electronic Health Record Review (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- OHSU Knight Cancer Institute — Portland, Oregon
- Fred Hutch — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (503) 494-5207
Email: kardosh@ohsu.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rectal Adenocarcinoma
- Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma — Tampa, Florida
- ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer — Portland, Oregon
- ctDNA-Informed Management of Early-Stage Rectal Cancer — Sacramento, California
- Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors — Hartford, Connecticut
- Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer — Houston, Texas
Explore by condition: All Rectal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.